Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 25;19(6):1479-1485.
doi: 10.22034/APJCP.2018.19.6.1479.

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir

Niyaz A Azad  1 , Zafar A Shah, Arshad A Pandith, Mosin S Khan, Roohi Rasool, Javed Rasool, Shiekh A Aziz
Affiliations

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir

Niyaz A Azad et al. Asian Pac J Cancer Prev. .

Abstract

Background: The prognostic significance of the common BCR-ABL transcripts like e13a2 (b2a2) and e14a2 (b3a2) in Chronic myeloid leukemia (CML) has been reported from patients treated with different tyrosine kinase inhibitors but its impact on clinical response and overall survival remains still unexplored. The aim of this study was to evaluate the prognostic significance of different transcript types in a cohort of CML patients treated with imatinib. Methods: A total 42 confirmed cases of Chronic Myeloid Leukemia (CML) patients were recruited into our cohort study and a multiplex Reverse Transcriptase-Polymerase Chain Reaction technique (RT-PCR) was used to detect 3 main transcript types ‘e1a2’, ‘e13a2’, and ‘e14a2’ found in CML. Results: Only two types of transcripts e13a2 (b2a2) and e14a2 (b3a2) were detected in our CML patients and none had the e1a2 type. All the patients were RT-PCR positive for either e13a2 or e14a2 fusion transcript demonstrating 100% concordance with their Ph+ve cytogenetic status at baseline. TLC count (range of 201-600x103/μl) and platelet count (range of 201-900x103/μl) at baseline were found to be associated more with the e14a2 (b3a2) than the e13a2 (b2a2) transcript type (p-value: 0.001). The two transcripts found did not relate significantly towards sex, age-group or indicated spleen size ranges as well as percentage ranges of blast cells. Conclusion: We conclude that there is no overall prognostic implication of either the e13a2 or the e14a2 transcript type across the spectrum of indicated clinical parameters evaluated. Even the overall survival analysis of the two transcript types revealed no prognostic association whatsoever.

Keywords: BCR-ABL; chronic myeloid leukemia; imatinib; survival; RT-PCR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gel Electrophoresis Documentation of BCR-ABL Transcripts in CML.
Figure 2
Figure 2
Kaplan Meier Analysis for Imatinib Resistance with Respect to Harboring e13a2 or e14a2 Transcript Type.
Figure 3
Figure 3
Kaplan Meier Analysis for Overall Survival with Respect to Harboring e13a2 or e14a2 Transcript Type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Arana-Trejo RM, Ruiz Sanchez E, Ignacio-Ibarra G, et al. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML) Clin Lab Haematol. 2002;24:145–50. - PubMed
    1. Balatzenko G, Vundinti BR, Margarita G. Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia-A possibleinfluence of mdr1 gene expression. Hematol Rep. 2011;3:e3. - PMC - PubMed
    1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212–14. - PubMed
    1. Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncol. 2002;19:141–50. - PubMed
    1. Claire ML, Robert JH, Athina G, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362–7. - PMC - PubMed

MeSH terms